CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 103 enrolled
Drug / intervention
rTPA Treatment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01197573
NCT01197573N/ACompleted
CompareCT.gov

Enhancing DCD Utilization With Thrombolytic Therapy

The Cleveland Clinic·interventional·Posted Sep 9, 2010·Updated Aug 28, 2018

In Brief

A clinical study evaluating rTPA Treatment and No TPA Treatment for Liver Transplantation and Kidney Transplantation. Completed, enrolled 103 participants across 2 sites.

Detailed Summary

We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality, and may ultimately result in a greater number of transplantable livers and kidneys.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Transplantation, Kidney Transplantation
CountriesUnited States
CollaboratorsHealth Resources and Services Administration (HRSA)

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2010
Enrollment StartApr 1, 2010
Primary CompletionOct 1, 2015
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.8 years ago

Interventions

rTPA Treatmentdrug

Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation

No TPA Treatmentother

Standard of Care